In this video, we take a closer look at how gene therapy is redefining treatment by targeting the underlying genetic cause of disease instead of just relieving symptoms. It is gaining real‑world relevance in rare diseases, blood disorders, eye diseases, neuromuscular conditions, and selected CNS indications, where a single intervention can offer long‑lasting benefit. The field is shifting from a one‑size‑fits‑all model toward a specialized toolbox, using platforms like AAV, lentiviral vectors, CRISPR, and base editing, with AAV remains a critical workhorse for in vivo delivery making vector choice a central strategic decision for companies. At the same time, gene therapy faces important challenges, including ultra‑high costs, immune responses, and lingering uncertainty about long‑term durability and real‑world outcomes.

Beyond the science, gene therapy is now a serious business and execution game, with multi‑billion‑dollar funding and deal activity concentrated around late‑stage and approved assets in oncology and rare diseases. However, success is no longer defined only by impressive clinical data; real winners are those who can secure vector supply, scale up manufacturing, ensure CMC comparability, manage immunogenicity, and design feasible redosing strategies. Looking ahead, the future frontier includes a shift toward in vivo gene editing, safer non‑viral delivery systems, AI‑driven design, and a push into broader indications with greater focus on access and equity. With more than 160 new trials annually by 2025 and flexible frameworks from the US FDA, EMA, and ICH de‑risk development and support wider adoption of next‑generation gene therapies.